Newport News, VA, August 22, 2022– ivWatch, LLC will host two webinars this fall to be broadcasted live globally at the end of September and in late October. As the nurse staffing crisis continues to make major impacts on hospitals globally, it is more important than ever to be vigilant in peripheral IV therapy, the most common invasive procedure performed worldwide.
ivWatch’s unique biosensor technology is the only in existence that can monitor and notify clinicians of infiltration events. Partnering with continuous monitoring solutions can help provide breathing room for clinicians as satisfaction declines and workflows become more taxing. The webinars will showcase both the clinical aspects and the legal implications that can arise if hospitals fail to adopt new technologies.
Participants can tune in on September 22, 2022, to hear globally published vascular access specialist and nurse practitioner, Roland Van Rens. Roland will host an hour-long webinar focusing on the “Early Identification of Infiltration Events – A Matter of Eyes or Device?” Following the presentation, Roland will host a Q&A session to answer live questions from participants. Beginning today, interested participants can register here: https://www.ivwatch.com/webinar-early-identification-of-infiltration-events/.
Additionally, viewers globally can participate in a second webinar on October 27, 2022, to hear the legal viewpoints from former Association for Vascular Access (AVA) Treasurer and Secretary Russ Nassof, JD as he discusses the difficult challenges that present a threat to not meeting best practices in IV therapy and how they can increase risk, liability, and potential harm to patients. To register for the upcoming webinar titled “The Perfect Legal Storm: Navigating the Minefield of IV Infiltrations, visit https://www.ivwatch.com/webinar-perfect-legal-storm/.
After the live webinars are complete, the recording of the event will be published on the same registration pages.
About ivWatch, LLC
ivWatch, LLC is a biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians can leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative IV site monitoring solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch, Facebook @ivWatchLLC, and LinkedIn @ivWatch-LLC, or visit www.ivWatch.com.
MEDIA CONTACT:
Erin Wendell
erin.wendell@ivwatch.com
Mobile (410) 952-3800